Cogent Biosciences (COGT) Capital Expenditures (2017 - 2026)

Cogent Biosciences (COGT) has 9 years of Capital Expenditures data on file, last reported at $449000.0 in Q1 2026.

• On a quarterly basis, Capital Expenditures fell 17.92% year-over-year to $449000.0 in Q1 2026; TTM through Mar 2026 was $1.5 million, a 38.67% increase from a year earlier, with the FY2025 full-year figure at $1.6 million, up 171.2% from the prior year.
• Capital Expenditures for Q1 2026 stood at $449000.0, down from $811000.0 in the prior quarter.
• Over the last five years, Capital Expenditures for COGT reached as high as $3.3 million in Q3 2022 and fell as low as $65000.0 in Q3 2025.
• Historically, Capital Expenditures has averaged $719705.9 across 5 years, with a median of $441000.0 in 2022.
• Across the five-year window, Capital Expenditures plunged 96.35% in 2023 and soared 981.33% in 2025, its largest moves.
• Year by year, Capital Expenditures stood at $2.0 million in 2022, then plunged by 83.99% to $315000.0 in 2023, then tumbled by 76.19% to $75000.0 in 2024, then surged by 981.33% to $811000.0 in 2025, then slumped by 44.64% to $449000.0 in 2026.
• Per Business Quant data, the three most recent Capital Expenditures figures were $449000.0 in Q1 2026, $811000.0 in Q4 2025, and $65000.0 in Q3 2025.